Research programme: anticancer bispecific antibody therapeutics - Dren Bio/Novartis
Latest Information Update: 23 Oct 2024
At a glance
- Originator Dren Bio; Novartis Pharmaceuticals
- Developer Dren Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer